TP53 and urothelial carcinoma: A 2019 study by Lee et al. revealed that IP exhibits fewer genetic alterations compared to urothelial carcinoma, lacking mutations in genes such as *TP53* and *FGFR3*, which are hallmarks of malignant urothelial tumors.